A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...

IMP761 is a first-in-class agonist LAG-3 antibody designed to restore balance to the immune system by enhancing the "brake” ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

The villains were injectable specialty drugs like Keytruda and inpatient surgical procedures for seriously ill patients.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

An FDA safety announcement regarding labeling changes for the commonly used oncology drugs capecitabine and 5-fluorouracil highlights a risk of dihydropyrimidine dehydrogenase deficiency, which can ...

Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer ...

We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take ...